文献速递湿疹皮炎与荨麻疹

Upadacitinib对比Dupilumab治疗中重度特应性皮炎16周IIIb/IV期随机对照研究

Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).
PubMed 文献 · Br J Dermatol · 2024-01-01

Level Up研究是一项全球随机开放标签评估者盲法IIIb/IV期研究,纳入对系统治疗应答不佳或不适合系统治疗的中重度特应性皮炎青少年和成人。患者随机接受Upadacitinib(UPA,15mg起始,根据应答增至30mg)或Dupilumab(DUPI)治疗16周。主要终点为第16周同时达到EASI 90和WP-NRS 0/1,UPA组为19.9%,DUPI组为8.9%(P < 0.001),UPA显示出优效性,所有排名次要终点均显示UPA优于DUPI,未发现新的安全性信号。

要点

  • UPA(15mg起始,按应答增至30mg)在第16周同时达到EASI 90和WP-NRS 0/1的比例显著高于DUPI(19.9% vs 8.9%,P < 0.001)。
  • UPA在所有排名次要终点(不同皮肤和瘙痒应答水平及时间点)均优于DUPI,事后分析显示最早第2天瘙痒应答率更高。
  • 安全性方面未发现新的信号,UPA组痤疮、头痛、感冒或某些感染(包括带状疱疹和疱疹性湿疹)更常见,DUPI组眼和眼睑炎症或关节疼痛更常见。

核心结论

  • 在中重度特应性皮炎青少年和成人中,UPA 15mg起始并按临床应答剂量递增至30mg,在第16周同时达到接近完全皮损清除(EASI 90)和几乎无瘙痒(WP-NRS 0/1)方面优于按标签使用的DUPI,且所有排名次要终点均显示优效性。

研究设计与样本

  • Level Up是一项全球、随机、开放标签、疗效评估者盲法的IIIb/IV期研究,纳入对系统治疗应答不佳或不适合系统治疗的中重度特应性皮炎青少年和成人,随机分配至UPA组或DUPI组治疗16周(第1期)。
  • UPA组起始剂量为15mg,若在第4周或之后未达到EASI 50或WP-NRS改善≥4分,或在第8周或之后未达到EASI 75,则剂量递增至30mg;DUPI组按标签使用。
  • 主要终点为第16周同时达到EASI 90和WP-NRS 0/1。

主要发现

  • 第16周同时达到EASI 90和WP-NRS 0/1的比例:UPA组19.9%,DUPI组8.9%(P < 0.001)。
  • UPA在所有排名次要终点上均优于DUPI,事后分析显示最早第2天瘙痒应答率更高。
  • 安全性方面未发现新的信号;UPA组痤疮、头痛、感冒或某些感染(包括带状疱疹和疱疹性湿疹)更常见,DUPI组眼和眼睑炎症或关节疼痛更常见。

临床怎么用

  • 对于中重度特应性皮炎且对系统治疗应答不佳或不适合系统治疗的患者,可考虑UPA 15mg起始并根据临床应答递增至30mg,以快速改善瘙痒和皮损。
  • 治疗选择时需权衡安全性:UPA组痤疮、头痛、感冒或某些感染(包括带状疱疹和疱疹性湿疹)更常见,DUPI组眼和眼睑炎症或关节疼痛更常见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic skin disease characterized by intense itch and eczematous skin lesions. Some patients with AD continue to experience flares and substantial clinical burden, despite ongoing systemic treatment. OBJECTIVES: To assess the efficacy and safety of once-daily upadacitinib (UPA), initiated at 15 mg and dose-escalated to 30 mg based on clinical response, compared with dupilumab (DUPI) as per its label, and present the week 16 primary analysis results. METHODS: Level Up is a phase IIIb/IV global randomized open-label efficacy assessor-blinded study evaluating UPA vs. DUPI in adolescents and adults with moderate-to-severe AD who had an inadequate response to systemic therapy or when use was inadvisable. Patients were randomized to UPA or DUPI for 16 weeks of treatment (period 1). Patients on UPA were started on 15 mg and dose-escalated to 30 mg if they did not achieve an Eczema Area and Severity Index reduction of at least 50% (EASI 50) or a ≥ 4-point Worst Pruritus Numerical Rating Scale (WP-NRS) improvement on or after week 4, or an EASI reduction of at least 75% (EASI 75) on or after week 8. The primary endpoint was simultaneous achievement of an EASI reduction of at least 90% (EASI 90) and WP-NRS 0/1 at week 16. Ranked secondary endpoints included skin and itch responses at varying response levels and timepoints. Safety measures were assessed throughout the study. RESULTS: Superior efficacy in achieving simultaneous EASI 90 and WP-NRS 0/1 response at week 16 was demonstrated with UPA vs. DUPI (19.9% vs 8.9%, respectively; P < 0.001). UPA showed superiority over DUPI for all ranked secondary endpoints, with post hoc analyses exhibiting higher itch response rates as early as day 2. No new safety signals were identified in this period. CONCLUSIONS: Treatment of moderate-to-severe AD with UPA, initiated at 15 mg and dose-escalated based on clinical response, demonstrated superiority over DUPI per its label for the primary endpoint of simultaneous achievement of near-complete skin clearance (EASI 90) and little-to-no itch (WP-NRS 0/1) at week 16, with all ranked secondary endpoints demonstrating superiority at varying skin and itch response levels and timepoints. No new safety signals were identified vs. the previously reported safety profiles of UPA and DUPI. Eczema, or atopic dermatitis, is a skin disease that causes severe itching and rashes. Some people who take medication for eczema still have trouble with itching or rashes that are severe enough to affect their daily life. Upadacitinib and dupilumab are medications that treat moderate-to-severe eczema. Each one works a little differently. This study compared how well upadacitinib or dupilumab treated moderate-to-severe eczema. Patients started with the lowest (15 mg) dose of upadacitinib. This was increased to 30 mg if itching or skin rashes were not improving after at least 4 weeks of taking it. Patients who were taking dupilumab stayed on the same dose. After 16 weeks, patients taking upadacitinib (15 mg or 30 mg) had more itching and rashes from eczema clear up faster than those taking dupilumab. The safety findings were consistent with what is already known about both drugs. No new safety concerns were found. Patients taking upadacitinib were more likely to have acne, headache, colds or certain types of infections, including shingles and a skin infection called eczema herpeticum, than patients taking dupilumab. Patients taking dupilumab were more likely to have inflammation of the eye and eyelids, or joint aches and pain than patients taking upadacitinib. Other findings were reported for both drugs. The results of this study found that upadacitinib was faster at getting rid of almost all itching and rashes from eczema than dupilumab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol. 2024. PMID: 39438067. doi:10.1093/bjd/ljae404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。